Related Experiment Video
Updated: Jul 16, 2026
04:00
A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells
Published on: September 7, 2011
FAK and Pyk2: Paralogous Kinases with Opposing Roles in Vasculogenic Mimicry in Triple-Negative Breast Cancer
Shilpa Madhavan-Kadali1, Tal Sneh1, Naamah Bloch1
1Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.
International Journal of Molecular Sciences
|July 15, 2026
Summary
Focal adhesion kinase (FAK) promotes vasculogenic mimicry (VM) in triple-negative breast cancer (TNBC), while proline-rich tyrosine kinase 2 (Pyk2) suppresses it. This identifies FAK as a potential therapeutic target to inhibit VM in TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Vasculogenic mimicry (VM) is a critical non-endothelial tumor vascularization process.
- VM is prevalent in triple-negative breast cancer (TNBC), contributing to metastasis and therapy resistance.
- The molecular drivers of VM in TNBC, particularly focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), are not well understood.
Purpose of the Study:
- To investigate the distinct roles of FAK and Pyk2 in regulating VM in TNBC.
- To analyze the clinical expression patterns of FAK and Pyk2 in relation to VM in TNBC patients.
Main Methods:
- Transcriptomic analysis using TNMplot V2, DepMap, and patient cohorts.
- In vitro tube formation assays in TNBC cells with FAK/Pyk2 knockdown or overexpression.
- Analysis of FAK and Pyk2 expression in independent patient cohorts (TCGA-BRCA, METABRIC).
Main Results:
- FAK knockdown impaired, while Pyk2 overexpression also impaired, VM network formation in vitro.
- Clinical data showed FAK upregulation in TNBC, inversely correlating Pyk2 with VM-associated gene expression.
- FAK and Pyk2 exhibit opposing, non-redundant roles in regulating VM.
Conclusions:
- FAK acts as a positive regulator of VM in TNBC.
- Pyk2 functions as a context-dependent suppressor of VM at elevated levels.
- FAK is a potential therapeutic target for inhibiting VM-driven tumor perfusion in TNBC.
Related Concept Videos
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...